Sylvester Comprehensive Cancer Center

E-mail a Friend

Alan W. Heldman, M.D.

General Information

Alan W. Heldman, M.D.

Languages

  • English

Certifications

  • American Board of Internal Med-Cardiovascular Disease

Specialties

  • Internal Medicine
  • Interventional Cardiology - Internal Medicine
  • Cardiovascular Disease - Internal Medicine

Roles

  • Interventional Cardiologist
  • Professor of Medicine, Cardiovacular Division

Clinical Interests

Complex and high-risk coronary intervention
Hypertrophic cardiomyopathy, including treatment with alcohol septal ablation
Techniques to reduce or eliminate complications from interventional procedures
Coronary restenosis
Stem cell therapy for myocardial infarction and heart failure

Non-surgical treatments for structural heart disease and valvular heart disease

Research Interests

Stem Cell Therapy for Myocardial Infarction and Heart Failure

Catheter Delivery of Stem Cells to the Heart

Non-surgical treatment of structural heart disease and valvular heart disease

Coronary Stent Design and Drug-Eluting Stents

Vein Graft Intervention and Protection Devices

Awards

Fellow, Society for Cardiovascular Angiography and Interventions

Education

1995 Fellowship
Johns Hopkins University
1994 Fellowship
Johns Hopkins University
1991 Residency
Johns Hopkins University
1988 M.D., with honors
University of Alabama at Birmingham
1984 A.B., cum laude
Harvard College

Publications

  • Heldman AW, Wu KC, Abraham TP, Cameron DE. Myectomy or alcohol septal ablation: Surgery and percutaneous intervention go another round. J Am Coll Cardiol. 2007 Jan 23;49(3):358-60.
  • Atiemo A, Conte JV, Heldman AW. Resuscitation and Recovery from Acute Right Ventricular Failure Using a Percutaneous Right Ventricular Assist Device. Catheterization and Cardiovascular Interventions 2006 Jun 8;68(1):78-82.
  • Amado LC, St John M, Saliaris AP, Xie J-S, Cattaneo S, Durand DJ, Fitton T, Kuang JQ, Stewart G, Brawn J, Eneboe V, Lehrke S, Baumgartner W, Martin BJ, Heldman AW, Hare JM. Cardiac Repair with Mesenchymal Stem Cells following Myocardial Infarction. Proceedings of the National Academy of Sciences 2005 Aug 9; 102(32):11474-9.
  • Gershlick A, De Scheerder I, Chevalier B, Camenzind E, Vrints C, Reifart N, Missault L, Goy J-J, Stephens-Lloyd A, Brinker J, Raizner E, Urban P, Heldman AW. Inhibition of Restenosis with a Paclitaxel-eluting polymer-free Coronary Stent: The European evaLUation of pacliTaxel Eluting Stent (ELUTES) Trial. Circulation. 2004;109:487-493.

Biography

Areas of Specialization

  • Complex and high-risk coronary intervention
  • Hypertrophic cardiomyopathy, including treatment with alcohol septal ablation
  • Techniques to reduce or eliminate complications from interventional procedures
  • Coronary restenosis
  • Stem cell therapy for myocardial infarction and heart failure

Alan W. Heldman, M.D., is clinical chief of cardiology at the University of Miami Miller School of Medicine, where he also holds an appointment as professor of medicine. Educated at Harvard College, University of Alabama at Birmingham School of Medicine, and trained in internal medicine, cardiovascular disease, and interventional cardiology all at Johns Hopkins University, Dr. Heldman spent 12 years on the faculty in cardiology at Johns Hopkins, where he was director of Interventional Cardiology Innovation & Research, a high volume interventional operator, and associate professor of medicine.

Dr. Heldman was a member of the first team to produce and test an effective drug-eluting stent, and he is expert in the treatment and prevention of coronary restenosis. He is involved with the development of new techniques to treat myocardial infarction and heart failure with the catheterdelivery of stem cells to the heart. His clinical practice focuses on techniques for a number of interventional problem areas, including procedures in the elderly, in vein graft disease, in acute myocardial infarction, and in patients with vascular disease. He also coordinates a multi-disciplinary clinical effort for the evaluation and care of patients with hypertrophic cardiomyopathy.

E-mail a Friend